Literature DB >> 25489485

Prevalence of diabetes and cardiovascular risk factors in middle-class urban participants in India.

Arvind Gupta1, Rajeev Gupta2, Krishna Kumar Sharma3, Sailesh Lodha2, Vijay Achari4, Arthur J Asirvatham5, Anil Bhansali6, Balkishan Gupta7, Sunil Gupta8, Mallikarjuna V Jali9, Tulika G Mahanta10, Anuj Maheshwari11, Banshi Saboo12, Jitendra Singh13, Prakash C Deedwania14.   

Abstract

OBJECTIVES: To determine the prevalence of diabetes and awareness, treatment and control of cardiovascular risk factors in population-based participants in India.
METHODS: A study was conducted in 11 cities in different regions of India using cluster sampling. Participants were evaluated for demographic, biophysical, and biochemical risk factors. 6198 participants were recruited, and in 5359 participants (86.4%, men 55%), details of diabetes (known or fasting glucose >126 mg/dL), hypertension (known or blood pressure >140/>90 mm Hg), hypercholesterolemia (cholesterol >200 mg/dL), low high-density lipoprotein (HDL) cholesterol (men <40, women <50 mg/dL), hypertriglyceridemia (>150 mg/dL), and smoking/tobacco use were available. Details of awareness, treatment, and control of hypertension and hypercholesterolemia were also obtained.
RESULTS: The age-adjusted prevalence (%) of diabetes was 15.7 (95% CI 14.8 to 16.6; men 16.7, women 14.4) and that of impaired fasting glucose was 17.8 (16.8 to 18.7; men 17.7, women 18.0). In participants with diabetes, 27.6% were undiagnosed, drug treatment was in 54.1% and control (fasting glucose ≤130 mg/dL) in 39.6%. Among participants with diabetes versus those without, prevalence of hypertension was 73.1 (67.2 to 75.0) vs 26.5 (25.2 to 27.8), hypercholesterolemia 41.4 (38.3 to 44.5) vs 14.7 (13.7 to 15.7), hypertriglyceridemia 71.0 (68.1 to 73.8) vs 30.2 (28.8 to 31.5), low HDL cholesterol 78.5 (75.9 to 80.1) vs 37.1 (35.7 to 38.5), and smoking/smokeless tobacco use in 26.6 (23.8 to 29.4) vs 14.4 (13.4 to 15.4; p<0.001). Awareness, treatment, and control, respectively, of hypertension were 79.9%, 48.7%, and 40.7% and those of hypercholesterolemia were 61.0%, 19.1%, and 45.9%, respectively.
CONCLUSIONS: In the urban Indian middle class, more than a quarter of patients with diabetes are undiagnosed and the status of control is low. Cardiovascular risk factors-hypertension, hypercholesterolemia, low HDL cholesterol, hypertriglyceridemia, and smoking/smokeless tobacco use-are highly prevalent. There is low awareness, treatment, and control of hypertension and hypercholesterolemia in patients with diabetes.

Entities:  

Keywords:  Cardiovascular; Hypercholesterolemia; Hypertension

Year:  2014        PMID: 25489485      PMCID: PMC4256307          DOI: 10.1136/bmjdrc-2014-000048

Source DB:  PubMed          Journal:  BMJ Open Diabetes Res Care        ISSN: 2052-4897


More than a quarter of patients with diabetes in the Indian urban middle class are undiagnosed. In patients with diabetes, cardiovascular risk factors—hypertension, hypercholesterolemia, low high-density lipoprotein cholesterol, and hypertriglyceridemia—are highly prevalent. The status of awareness, treatment, and control of hypertension and hypercholesterolemia is low.

Introduction

Diabetes is endemic in India.1–3 The International Diabetes Federation has estimated that India currently has more than 65 million people with type 2 diabetes and the numbers are poised to double in the next 20 years.1 It has been reported that the prevalence of diabetes among urban participants in India is among the highest in the world and comparable to the high prevalence countries of West Asia and the Pacific.3 4 Cardiovascular diseases (coronary heart disease, stroke, peripheral arterial disease) are the major causes of morbidity and mortality in type 2 diabetes. It has been reported that 60–80% of patients with diabetes die of cardiovascular events.5 6 Reasons for the increased risk include the high prevalence of major cardiovascular risk factors (hypertension, lipid abnormalities, and smoking) as well as factors specific to diabetes (hyperglycemia, diabetic dyslipidemia, and oxidation-related and glycation-related vascular injury).7 Control of cardiovascular risk factors in diabetes can prevent or delay cardiovascular events. Studies have reported that therapies directed toward the control of blood pressure (BP) and low density lipoprotein (LDL) cholesterol can significantly decrease macrovascular events in diabetes.8 9 In India, a high prevalence of metabolic cardiovascular risk factors has been reported among clinic-based patients with diabetes.10 Only a few population-based studies in India have determined the prevalence of various cardiovascular risk factors in patients with diabetes.11–13 No study has evaluated the status of awareness, treatment and control of hypertension and hypercholesterolemia in population-based patients with diabetes . Therefore, we performed this study to determine the prevalence of diabetes, impaired fasting glycemia (IFG) and various cardiovascular risk factors in population-based patients in India with diabetes. We also studied the awareness, treatment, and control of hypertension and hypercholesterolemia, two of the most important cardiovascular risk factors.

Methods

A multisite study to identify the prevalence of cardiovascular risk factors and their sociodemographic determinants was conducted among middle-class urban participants in India.14–17 The rationale for the study has been reported.18 The protocol was approved by the institutional ethics committee of the national coordinating center. Written informed consent was obtained from each participant. The study case report form was developed according to the guidelines of the WHO.19

Regions and investigators

We planned the study to identify the prevalence of cardiometabolic risk factors and their determinants in middle-class urban participants in India.18 Briefly, medium-sized cities were identified in each of the large states of India and investigators with track record of research in cardiovascular or diabetes epidemiology were invited. A steering committee and investigators meeting was organized at the initiation of the study where the study protocol was discussed and developed. The meeting was followed by training in the salient features of the questionnaire and techniques of examination and evaluation to ensure uniformity in recruitment and data collection. Eleven investigators in 11 cities finally performed the survey.14 These cities are distributed in all the geographic regions of the country—northern (Jammu, Chandigarh), western (Bikaner, Ahmedabad), southern (Belgaum, Madurai), central (Nagpur, Jaipur), and eastern (Lucknow, Patna, Dibrugarh).

Sampling

The study data were collected in the years 2006–2010 at various locations. Simple cluster sampling was performed at each site. A middle-class location was identified at each city by the investigator. The middle-class location is based on municipal classification and is derived from the cost of land, type of housing, public facilities (roads, sanitation, water supply, electricity, gas supply, etc), and educational and medical facilities as reported earlier.14 A sample size of about 250 men and 250 women (n=500) at each site is considered adequate by the WHO to identify a 20% difference in the mean level of biophysical and biochemical risk factors.19 We invited 800–1000 participants in each location to ensure participation of at least 500 participants at each site, estimating a response of 70% as observed in previous studies.20 At each site, a uniform protocol of recruitment was followed. A locality within the urban area of the city was identified on ad hoc basis by each investigator, houses enumerated, number of participants >20 years living in each house determined and all these individuals were invited to a local community center or healthcare facility (clinic, dispensary) for examination and blood investigations. This procedure ensured that the study was representative even if the survey was prematurely abandoned.14 The surveys were preceded by meetings with community leaders to ensure good participation. Participants were invited in the fasting state to a community center or medical center within each locality, either twice or thrice a week, depending on the investigator's schedule.

Measurements

The study case report form was filled by the research worker after details were inquired from the participant. Apart from demographic history, details of socioeconomic status based on educational status and years of formal education, type of family, any major previous illnesses, history of known hypertension, diabetes, lipid abnormalities, and cardiovascular disease were inquired. Smoking details were inquired for the type of smoking or tobacco use, number of cigarettes or bidis smoked, and years of smoking or smokeless tobacco use. Intake of alcohol was assessed as drink per week. Details of other diet and physical activity were inquired using focused questions.14 All the equipments for measurements of height, weight, waist and hip size, and BP were similar at the centers to ensure uniformity. Height and weight were measured using a stadiometer and calibrated weighing machines, respectively, and waist and hip circumference was measured using the WHO guidelines.19 Sitting BP was measured after at least 5 min rest using standardized instruments. Three readings were obtained and were averaged for the data analysis. A fasting blood sample was obtained from all individuals after at least 8–10 h fast. The blood samples were obtained at community centers by technicians from an accredited national laboratory—Thyrocare Technologies Ltd, Mumbai, India (http://www.thyrocare.com). Blood glucose was measured at the local biochemistry facility of these laboratories. Blood for cholesterol, cholesterol lipoproteins, and triglyceride estimation was transported under ambient temperature to the national referral laboratory at Mumbai. All the blood samples were analyzed at a single laboratory and a uniform protocol was used for measurements.16 Cholesterol, high-density lipoprotein (HDL) cholesterol, and triglyceride levels were measured using enzyme-based assays with internal and external quality control. LDL cholesterol was calculated using Friedwald's formula.16

Diagnostic criteria

Smokers included participants who smoked cigarettes, bidis, or other smoked forms of tobacco daily, while past smokers were participants who had smoked for at least 1 year and had stopped more than a year ago. Use of other forms of tobacco (oral, nasal, etc) was classified as smokeless tobacco. Individuals with greater than moderate physical activity (30 min of work-related or leisure-time physical activity, >5 times a week) were classified as moderately active. Those with a high dietary intake of visible fat (>30 g visible fat intake/day) and ≤2 dishes of fruits or green vegetables/day were classified as having an unhealthy diet. Hypertension was diagnosed when systolic BP was >140 mm Hg and/or diastolic BP was >90 mm Hg or a person was a known hypertensive.15 Hypercholesterolemia was defined by total cholesterol >200 mg/dL, low HDL cholesterol by levels <40 mg/dL in men and <50 mg/dL in women, and hypertriglyceridemia as >150 mg/dL.16 Diabetes was diagnosed when either a participant was diagnosed by a physician or the fasting blood glucose was >126 mg/dL. Participants with fasting glucose 100–125 mg/dL were diagnosed as those with IFG. Known diabetes by history, those on any drug therapy as being on treatment, and control was defined by fasting glucose ≤130 mg/dL according to American Diabetes Association/European Association of Study of Diabetes criteria.21 The prevalence of various cardiovascular risk factors was determined in participants with and without diabetes. The status of awareness, treatment, and control of hypertension and hypercholesterolemia was also determined using previous definitions.15 16 Hypertension control was defined when systolic BP was <140 mm Hg and diastolic BP was <90 mm Hg. Controlled hypercholesterolemia was defined by the presence of total cholesterol <200 mg/dL.21

Statistical analyses

All the data were entered into the SPSS database (V.10.0, SPSS Inc, Chicago, Illinois, USA). More than 90% of the data for various variables were available, and in about 85% of participants the data for all the variables were available. Categorical variables are reported as per cent and 95% CIs. The prevalence of diabetes and IFG in various age groups is reported. Age-related trends were examined by the Mantel-Haenszel χ2 test. Age adjustment was performed using the direct method with the 2001 Indian census population as the standard. Prevalence (%) of various risk factors in participants with diabetes and without diabetes is reported and significance of differences evaluated using χ2 test. p Values <0.05 are considered significant.

Results

The study was performed at 11 cities located in all geographic regions of India as reported earlier.14 In total, 6198 participants (men 3426, women 2772) of the targeted 9900 participants were evaluated (response 62%). Recruitment at individual sites and data for social and demographic characteristics in men and women have been reported.14 Among 5359 participants (men 54.8%, women 45.2%), details of diabetes and various cardiovascular risk factors were available, and therefore these data have been used in the present study. The age-specific prevalence (%) of diabetes and IFG and 95% CI is shown in table 1. There is a significant age-associated increase in the prevalence of diabetes in men and women (p<0.001). The age-adjusted prevalence of diabetes was 15.7% (CI 14.8% to 16.6%); in men, it was 16.7% (CI 15.4% to 17.9%), and in women it was 14.4% (13.1% to 15.7%). The age-adjusted prevalence of IFG was 17.8% (CI 16.8% to 18.7%); in men, it was 17.7% (CI 16.4% to 19.0%), and in women it was 18.0% (CI 16.6% to 19.4%). The prevalence of IFG was greater than that of diabetes in the younger age groups and lower in the older age groups (figure 1). The prevalence of diabetes and IFG equalized at a younger age in men as compared with women (table 1). The prevalence of any dysglycemia (diabetes or IFG) also shows an age-associated increase and is present in more than 60% among older participants (figure 1).
Table 1

Age-specific prevalence of diabetes and impaired fasting glycemia in men and women

Age groupMen
Women
Total
Diabetes (known and/or fasting glucose >126 mg/dL)Impaired fasting glucose (100–125 mg/dL)Diabetes (known and/or fasting glucose >126 mg/dL)Impaired fasting glucose (100–125 mg/dL)Diabetes (known and/or fasting glucose >126 mg/dL)Impaired fasting glucose (100–125 mg/dL)
<303.8 (2.5 to 5.1)13.7 (11.2 to 16.2)6.0 (4.0 to 8.0)9.8 (7.4 to 12.2)4.8 (3.7 to 5.9)12.0 (10.2 to 13.7)
30–3914.5 (12.1 to 16.9)19.3 (16.4 to 22.2)8.9 (6.5 to 11.3)23.7 (20.3 to 27.1)11.7 (10.0 to 13.4)21.5 (19.3 to 23.7)
40–4927.6 (24.6 to 30.6)26.0 (22.8 to 29.2)18.6 (15.4 to 21.8)22.7 (19.3 to 26.0)23.4 (21.2 to 25.6)24.5 (22.2 to 26.8)
50–5935.7 (32.5 to 38.9)25.1 (21.9 to 28.3)33.6 (29.7 to 37.5)27.4 (23.8 to 31.0)34.8 (32.3 to 37.3)26 (23.6 to 28.4)
60–6941.0 (37.7 to 44.3)26.7 (23.4 to 29.9)36 (32.0 to 40.0)30.1 (26.4 to 33.8)38.7 (36.1 to 41.2)28.3 (25.8 to 30.7)
70+40.8 (37.5 to 44.1)30.6 (27.2 to 34.0)42.1 (38.0 to 46.2)33.3 (29.5 to 37.1)41.2 (38.6 to 43.8)31.5 (29.0 to 34.0)
Age-adjusted16.7 (15.4 to 17.9)17.7 (16.4 to 19.0)14.4 (13.1 to 15.7)18.0 (16.6 to 19.4)15.7 (14.8 to 16.6)17.8 (16.8 to 18.7)
Figure 1

Age-specific prevalence of diabetes, impaired fasting glycemia (IFG), and any dysglycemia.

Age-specific prevalence of diabetes and impaired fasting glycemia in men and women Age-specific prevalence of diabetes, impaired fasting glycemia (IFG), and any dysglycemia. Of the study participants with diabetes, presence of known disease was in 72.4% (CI 69.6% to 75.2%) and was greater in older participants (table 2). Almost a quarter were undiagnosed (27.6%, CI 24.8% to 30.4%). Of the total patients with diabetes, drug treatment was present in 54.1% (CI 51.0% to 57.2%), and in those with previous diagnosis it was present in 74.7% (CI 71.8% to 77.6%). The status of diabetes control was defined using fasting glucose <130 mg/dL.21 Among all patients with diabetes, control was present in 39.6% (CI 36.5% to 42.7%), and in those with previously diagnosed diabetes it was present in 48.2% (CI 44.5% to 51.9%).
Table 2

Prevalence (%, 95% CI) of diabetes and status of diagnosis, treatment, and control in various age groups

Age groupNumbersDiabetes (known and/or fasting glucose >126 mg/dL)Known diabetesUndiagnosedTreatmentControl, fasting glucose ≤130 mg/dL
<304174.7 (2.7 to 6.7)30.0 (27.3 to 32.7)70.0 (64.8 to 75.2)15.0 (12.6 to 17.5)35.0 (30.4 to 39.6)
30–3997611.7 (9.7 to 13.7)58.8 (55.9 to 61.7)41.2 (35.6 to 46.8)37.7 (34.4 to 40.9)34.2 (31.2 to 37.2)
40–49144523.4 (21.2 to 25.6)75.7 (73.2 to 78.2)24.3 (19.4 to 29.2)53.8 (50.4 to 57.1)38.1 (35.6 to 40.6)
50–59131334.8 (32.2 to 37.4)82.7 (80.5 to 84.9)17.2 (12.9 to 21.5)63.0 (59.7 to 66.2)43.3 (40.6 to 46.0)
60–6985938.7 (35.4 to 41.9)85.2 (83.1 to 87.3)14.7 (10.7 to 18.7)70.9 (67.8 to 73.9)42.0 (38.7 to 45.3)
70+34941.2 (36.0 to 46.4)81.9 (79.6 to 84.2)22.8 (18.0 to 22.6)67.4 (64.2 to 70.5)46.5 (41.3 to 51.7)
Age-adjusted535915.7 (14.7 to 16.7)72.4 (69.6 to 75.2)27.6 (24.8 to 30.4)54.1 (51.0 to 57.2)39.6 (36.5 to 42.7)
Prevalence (%, 95% CI) of diabetes and status of diagnosis, treatment, and control in various age groups The age-specific prevalence of various risk factors in participants with diabetes is shown in table 3. Among participants with diabetes versus those without, age-adjusted prevalence of hypertension was in 73.1% (CI 67.2% to 75.0%) vs 26.5% (CI 25.2% to 27.8%), hypercholesterolemia in 41.4% (CI 38.3% to 44.5%) vs 14.7% (CI 13.7% to 15.7%), low HDL cholesterol in 78.5% (CI 75.9% to 80.1%) vs 37.1% (CI 35.7% to 38.5%), hypertriglyceridemia in 71.0% (CI 68.1% to 73.8%) vs 30.2% (CI 28.8% to 31.5%), and smoking and/or smokeless tobacco use in 26.6% (CI 23.8% to 29.4%) vs 14.4% (CI 13.4% to 15.4%); (p<0.01; figure 2). The prevalence of smoking was in 18.2% vs 8.9% while that of smokeless tobacco use was present in 13.5% vs 7.9% (p<0.01). In known patients with diabetes versus others, hypertension awareness (79.9% vs 43.2%), treatment (48.7% vs 31.3%), and control (40.7% vs 20.6%) as well as hypercholesterolemia awareness (61.0% vs 12.0%), treatment (19.1% vs 5.0%), and control (total cholesterol <200 mg/dL, 45.9% vs 6.8%; LDL cholesterol <100 mg/dL, 66.5% vs 8.6%) were significantly greater (p<0.01; figure 3).
Table 3

Prevalence (%, 95% CIs) of various cardiovascular risk factors in participants with diabetes

Age groupHypertension
Hypercholesterolemia
Hypertriglyceridemia
HDL<40/50
Smoking/tobacco use
DiabetesNon-diabetesDiabetesNon-diabetesDiabetesNon-diabetesDiabetesNon-diabetesDiabetesNon-diabetes
<3045 (41.6 to 48.6)15.5 (13.3 to 16.9)20 (16.1 to 23.9)4 (2.7 to 5.3)45 (41.4 to 48.6)26.7 (24.4 to 28.9)75.0 (71.4 to 78.6)46.6 (44.1 to 49.1)20 (15.0 to 25.0)12 (9.6 to 14.4)
30–3939.5 (36.2 to 42.8)20.5 (18.4 to 22.5)27.2 (22.9 to 31.5)9.6 (7.7 to 11.5)49.1 (45.4 to 52.7)33.4 (31.0 to 35.8)54.3 (50.2 to 58.4)48.1 (45.6 to 50.6)18.4 (13.6 to 23.2)16.6 (13.8 to 19.3)
40–4956.5 (53.2 to 59.8)33.6 (31.2 to 36.0)33.4 (28.8 to 38.0)20.1 (17.5 to 22.7)55.9 (52.3 to 59.-5)42.1 (39.6 to 44.6)44.1 (40.0 to 48.2)39.1 (36.7 to 41.5)16.5 (11.9 to 21.1)17.6 (14.8 to 20.4)
50–5958.4 (55.1 to 61.7)49.2 (46.7 to 51.7)37.2 (32.5 to 41.9)33.3 (30.2 to 36.4)52.7 (49.0 to 56.3)39.4 (36.9 to 41.9)42.9 (38.8 to 47.0)35.3 (32.9 to 37.7)19.3 (14.4 to 24.2)23.2 (20.1 to 26.3)
60–6968.4 (65.3 to 71.5)58.9 (56.4 to 61.4)39.6 (34.8 to 44.3)23.3 (20.5 to 26.1)48.3 (44.6 to 51.9)38.2 (35.7 to 40.7)32.4 (28.5 to 36.2)31.4 (29.1 to 33.7)17.1 (12.4 to 21.8)17.5 (14.7 to 20.3)
70+75.7 (72.8 to 78.6)70.2 (67.9 to 72.5)34.0 (29.4 to 38.6)46.3 (43.0 to 49.5)42.3 (38.7 to 45.9)33.6 (31.2 to 36.0)23.6 (20.1 to 27.1)19.5 (17.5 to 21.5)15.3 (10.8 to 19.8)15.6 (12.9 to 18.3)
Age-adjusted73.1 (67.2 to 73.0)26.5 (25.2 to 27.8)41.4 (38.3 to 44.5)14.7 (13.7 to 15.7)71.0 (68.1 to 73.8)30.2 (28.8 to 31.5)78.5 (75.9 to 80.1)37.1 (35.7 to 38.5)26.6 (23.8 to 29.4)14.4 (13.4 to 15.4)

HDL, high-density lipoprotein.

Figure 2

Age-adjusted prevalence of various cardiovascular risk factors in diabetes and others. The prevalence of all risk factors is significantly greater in diabetes (p<0.01). HDL, high density lipoprotein cholesterol; values of cholesterol and triglycerides are in mg/dL.

Figure 3

Status of awareness, treatment, and control of hypertension and hypercholesterolemia (total cholesterol >200 mg/dL) in study participants with known diabetes and others.

Prevalence (%, 95% CIs) of various cardiovascular risk factors in participants with diabetes HDL, high-density lipoprotein. Age-adjusted prevalence of various cardiovascular risk factors in diabetes and others. The prevalence of all risk factors is significantly greater in diabetes (p<0.01). HDL, high density lipoprotein cholesterol; values of cholesterol and triglycerides are in mg/dL. Status of awareness, treatment, and control of hypertension and hypercholesterolemia (total cholesterol >200 mg/dL) in study participants with known diabetes and others.

Discussion

The International Diabetes Federation has reported that the prevalence of diabetes in adults in India is 7.1%. The prevalence in urban areas is 9%.1 This study shows a greater prevalence among the middle-class urban Indians. The study also shows that participants with diabetes have a high prevalence of major cardiovascular risk factors—hypertension, hypercholesterolemia, low HDL cholesterol, and high triglycerides. The status of diabetes control as well as treatment and control of two important cardiovascular risk factors (hypertension and hypercholesterolemia) is low. Previous studies in India have reported a greater diabetes prevalence in urban adults as compared with rural adults.2–4 Recent studies have reported urban diabetes prevalence rates of 8–20% and rural diabetes prevalence rates of 5–15%.2 There are only a few multisite studies of diabetes prevalence in India. Using criteria similar to that used in this study, the Indian Industrial Population Surveillance Study evaluated the prevalence of diabetes at seven industrial sites in the country and reported a diabetes prevalence of 8%.22 The Indian Women's Health Study evaluated diabetes in middle-aged women, 35–70 years, in different rural and urban locations of the country and reported diabetes in 2.2% rural and 9.3% urban women.23 The India Migration Study reported diabetes in 13.5% urban, 14.3% migrant, and 6.2% rural participants.24 Multisite studies such as DESI,25 PODIS,26 and INDIAB27 used fasting as well as 2 h glucose estimation for diagnosis of diabetes, and therefore the results are not comparable to those of this study. Regional studies have reported a greater prevalence of diabetes in Southern India as compared with the north, east, and central India.2 4 This study reports a prevalence of 15.7%, which is similar to that reported in recent studies from India. We have not presented data on the regional differences in diabetes prevalence due to the small sample sizes (500–1000) at different locations. However, we have earlier shown that regional differences in diabetes prevalence are related more to the Social Development Index28 of the cities and not to the geography; cities with lower poverty indices and better social development indices have a greater prevalence of diabetes and other cardiometabolic risk factors.29 These results are similar to those of studies from China30 and other middle-income countries.31 Larger and more comprehensive studies are required to identify regional differences in diabetes and to evaluate the causes of these differences.32 This study also shows a high prevalence of major cardiovascular risk factors (hypertension, hypercholesterolemia, low HDL cholesterol, hypertriglyceridemia, and smoking/smokeless tobacco use) in participants with diabetes (figure 2). This finding is similar to those from studies from other parts of the world.6 7 The greater prevalence of smoking as well as smokeless tobacco use in participants with diabetes is an important finding and is similar to those of previous Indian studies.33 Another important finding is the low prevalence of these risk factors in the population without diabetes and suggests that diabetes is a major driver of cardiometabolic risks in India.7 A high prevalence of undiagnosed diabetes in younger participants (<40 years) is also important and highlights the importance of surveillance and screening among the younger populations for early diagnosis of diabetes in India. This study also shows that diabetes is associated with multiple cardiovascular risk factors and its prevention and elimination can have important consequences for cardiovascular disease prevention. The prevalence of known diabetes in this study is more than 70% of all individuals with diabetes and is more than those shown by previous reports from India.11–13 We studied the urban middle-class participants and found that the greater prevalence of known diabetes in this population was indicative of greater health literacy.14 We have previously reported higher awareness of hypertension in the present study participants15, this is similar to high awareness of diabetes in the present study. However, only half of the patients with diabetes are controlled to the target of fasting glucose <130 mg/dL. This is similar to previous reports from India.11 The American Diabetes Association and the European Association for Study of Diabetes recommend three markers for the assessment of diabetes control (blood fasting glucose, postprandial glucose, or glycated hemoglobin (HbA1c)).21 We defined control using fasting glucose levels only and did not measure blood HbA1c. This is an important study limitation. The low status of awareness, treatment, and control of cardiovascular risk factors among participants with diabetes is also an important finding in this study. Only a few international studies have evaluated the status of cardiovascular risk factor control in patients with diabetes. Gakidou et al34 compared the management of diabetes and associated cardiovascular risk factors in seven countries (Colombia, England, Iran, Mexico, Scotland, Thailand, and the USA). This study reported that a substantial proportion of individuals with diabetes remain undiagnosed and untreated in various developed and developing countries and ranged from 24% in Scotland and the USA to 62% in Thailand. The proportion of individuals with diabetes reaching treatment targets for blood glucose, systolic BP, and cholesterol ranged from 1% in Mexico to 12% in the USA.34 Low control of diabetes and hypertension has also been reported in a study in India.35 Our study also shows a low status of control of hypertension and hypercholesterolemia. More studies are required to confirm these findings. The greater awareness, treatment, and control of cardiovascular risk factors in participants with known diabetes observed in this study (figure 3) is similar to that reported in studies in the USA.36 Other limitations of the study are biases introduced because of sampling, non-representation of the Indian population, inclusion of only urban participants, low response rates, measurement techniques, and failure to correct for regression dilution. However, many of the limitations are inherent in a cross-sectional epidemiological study and the data are therefore subject to similar biases.14 Urban locations are hotbeds of the cardiovascular disease epidemic in India,4 and this study is therefore important. Moreover, similar methodology has been used in previous Indian studies and the present data are similarly representative.18 The low response rate in the study (62%) is also a matter of concern and it is possible that those excluded were either more or less healthy as compared with the study participants; however, these response rates are similar to those of other population-based studies in India and elsewhere19 and are within acceptable limits.37 Finally, there are multiple determinants of awareness, treatment, and control of cardiovascular risk factors in patients with diabetes. We have not analyzed the ‘causes of the causes’ or the societal factors38 that lead to greater cardiovascular risk and better awareness of risk factors in study participants. On the other hand, the strengths of the study include a nationwide scope and study of multiple risk factors. In conclusion, our nationwide study shows that the prevalence of diabetes among the urban middle-class participants in India is greater than that reported by the International Diabetes Federation.1 There is a low status of treatment and control. This study also shows a high prevalence of multiple cardiovascular risk factors among participants with diabetes. The low status of control of hypertension and hypercholesterolemia in participants with known diabetes is a cause for concern. Suitable strategies for improvement of risk factor management and control should be developed in India to prevent premature cardiovascular disease in diabetes.
  32 in total

1.  Prevalence of diabetes and prediabetes (impaired fasting glucose and/or impaired glucose tolerance) in urban and rural India: phase I results of the Indian Council of Medical Research-INdia DIABetes (ICMR-INDIAB) study.

Authors:  R M Anjana; R Pradeepa; M Deepa; M Datta; V Sudha; R Unnikrishnan; A Bhansali; S R Joshi; P P Joshi; C S Yajnik; V K Dhandhania; L M Nath; A K Das; P V Rao; S V Madhu; D K Shukla; T Kaur; M Priya; E Nirmal; S J Parvathi; S Subhashini; R Subashini; M K Ali; V Mohan
Journal:  Diabetologia       Date:  2011-09-30       Impact factor: 10.122

2.  Non-communicable diseases (diabetes, obesity and hyperlipidaemia) in urban slums.

Authors:  Anoop Misra; Ravindra Mohan Pandey; Rekha Sharma
Journal:  Natl Med J India       Date:  2002 Jul-Aug       Impact factor: 0.537

3.  Methods for establishing a surveillance system for cardiovascular diseases in Indian industrial populations.

Authors:  K S Reddy; D Prabhakaran; V Chaturvedi; P Jeemon; K R Thankappan; L Ramakrishnan; B V M Mohan; C S Pandav; F U Ahmed; P P Joshi; R Meera; R B Amin; R C Ahuja; M S Das; T M Jaison
Journal:  Bull World Health Organ       Date:  2006-06-21       Impact factor: 9.408

4.  Management of diabetes and associated cardiovascular risk factors in seven countries: a comparison of data from national health examination surveys.

Authors:  Emmanuela Gakidou; Leslie Mallinger; Jesse Abbott-Klafter; Ramiro Guerrero; Salvador Villalpando; Ruy Lopez Ridaura; Wichai Aekplakorn; Mohsen Naghavi; Stephen Lim; Rafael Lozano; Christopher J L Murray
Journal:  Bull World Health Organ       Date:  2010-11-22       Impact factor: 9.408

Review 5.  Epidemiology of cardiovascular disease in type 2 diabetes: the Indian scenario.

Authors:  Viswanathan Mohan; Janarthanan Vijay Venkatraman; Rajendra Pradeepa
Journal:  J Diabetes Sci Technol       Date:  2010-01-01

6.  Normotension, prehypertension, and hypertension in urban middle-class subjects in India: prevalence, awareness, treatment, and control.

Authors:  Rajeev Gupta; Prakash C Deedwania; Vijay Achari; Anil Bhansali; Bal Kishan Gupta; Arvind Gupta; Tulika G Mahanta; Arthur J Asirvatham; Sunil Gupta; Anuj Maheshwari; Banshi Saboo; Mallikarjuna V Jali; Jitendra Singh; Soneil Guptha; Krishna Kumar Sharma
Journal:  Am J Hypertens       Date:  2013-01       Impact factor: 2.689

7.  Diabetes in Asia.

Authors:  Ambady Ramachandran; Ronald Ching Wan Ma; Chamukuttan Snehalatha
Journal:  Lancet       Date:  2009-10-28       Impact factor: 79.321

8.  High prevalence of metabolic syndrome among urban subjects in India: a multisite study.

Authors:  Prakash C Deedwania; Rajeev Gupta; Krishna Kumar Sharma; Vijay Achari; Balkishan Gupta; Anuj Maheshwari; Arvind Gupta
Journal:  Diabetes Metab Syndr       Date:  2014-05-20

9.  Association between socioeconomic status and self-reported diabetes in India: a cross-sectional multilevel analysis.

Authors:  Daniel J Corsi; S V Subramanian
Journal:  BMJ Open       Date:  2012-07-18       Impact factor: 2.692

Review 10.  Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Authors:  Silvio E Inzucchi; Richard M Bergenstal; John B Buse; Michaela Diamant; Ele Ferrannini; Michael Nauck; Anne L Peters; Apostolos Tsapas; Richard Wender; David R Matthews
Journal:  Diabetes Care       Date:  2012-04-19       Impact factor: 19.112

View more
  19 in total

1.  Geographic epidemiology of cardiometabolic risk factors in middle class urban residents in India: cross-sectional study.

Authors:  Rajeev Gupta; Krishna Kumar Sharma; Bal Kishan Gupta; Arvind Gupta; Banshi Saboo; Anuj Maheshwari; Tulika Mahanta; Prakash C Deedwania
Journal:  J Glob Health       Date:  2015-06       Impact factor: 4.413

2.  Association of low educational status with microvascular complications in type 2 diabetes: Jaipur diabetes registry-1.

Authors:  Niharikaa Sharma; Surendra Kumar Sharma; Vitthal D Maheshwari; Krishna Kumar Sharma; Rajeev Gupta
Journal:  Indian J Endocrinol Metab       Date:  2015 Sep-Oct

3.  Association of low educational status with microvascular complications in type 2 diabetes: Jaipur diabetes registry.

Authors:  Niharikaa Sharma; Surendra Kumar Sharma; Vitthal D Maheshwari; Krishna Kumar Sharma; Rajeev Gupta
Journal:  Indian J Endocrinol Metab       Date:  2015 Nov-Dec

4.  Evaluation of statin prescriptions in type 2 diabetes: India Heart Watch-2.

Authors:  Rajeev Gupta; Sailesh Lodha; Krishna K Sharma; Surendra K Sharma; Sunil Gupta; Arthur J Asirvatham; Bhupendra N Mahanta; Anuj Maheshwari; Dinesh C Sharma; Anand S Meenawat; Raghubir S Khedar
Journal:  BMJ Open Diabetes Res Care       Date:  2016-08-18

5.  Serum uric acid and low-density lipoprotein cholesterol levels are independent predictors of coronary artery disease in Asian Indian patients with type 2 diabetes mellitus.

Authors:  C A Jayashankar; Henley Punnen Andrews; Venkata BharatKumar Pinnelli; Basappaji Shashidharan; H N Nithin Kumar; Swaapnika Vemulapalli
Journal:  J Nat Sci Biol Med       Date:  2016 Jul-Dec

6.  Identifying gaps in the continuum of care for hypertension and diabetes in two Indian communities.

Authors:  Rose Gabert; Marie Ng; Ruchi Sogarwal; Miranda Bryant; R V Deepu; Claire R McNellan; Sunil Mehra; Bryan Phillips; Marissa Reitsma; Blake Thomson; Shelley Wilson; Alexandra Wollum; Emmanuela Gakidou; Herbert C Duber
Journal:  BMC Health Serv Res       Date:  2017-12-27       Impact factor: 2.655

7.  PROMETHEUS: an observational, cross-sectional, retrospective study of hypertriglyceridemia in Russia.

Authors:  Yuri Karpov; Yunona Khomitskaya
Journal:  Cardiovasc Diabetol       Date:  2015-08-25       Impact factor: 9.951

8.  Perceptions and practices related to diabetes reported by persons with diabetes attending diabetic care clinics: The India 11-city 9-state study.

Authors:  Murthy V S Gudlavalleti; Raghupathy Anchala; Aashrai Sai Venkat Gudlavalleti; Srikrishna S Ramachandra; Rajan Shukla; A T Jotheeswaran; R Giridhara Babu; Vivek Singh; Komal Allagh; Jayanti Sagar; Souvik Bandyopadhyay; Clare E Gilbert
Journal:  Indian J Endocrinol Metab       Date:  2016-04

9.  Prevalence, Awareness, Treatment and Control of Diabetes Mellitus in a Chinese Population.

Authors:  Jiqiang Yue; Xuhua Mao; Kun Xu; Lingshuang Lü; Sijun Liu; Feng Chen; Jianming Wang
Journal:  PLoS One       Date:  2016-04-20       Impact factor: 3.240

10.  Situational analysis of services for diabetes and diabetic retinopathy and evaluation of programs for the detection and treatment of diabetic retinopathy in India: Methods for the India 11-city 9-state study.

Authors:  G V S Murthy; Clare E Gilbert; Rajan Shukla; Praveen Vashist; B R Shamanna
Journal:  Indian J Endocrinol Metab       Date:  2016-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.